COVID-19 vaccine trials for children have begun in Ohio. When could the shot be approved for kids?

Now that anyone over the age of 12 is eligible to get a COVID-19 vaccine, attention has turned to when younger children might be able to get the shot.

Read the full article here

Aventiv Research Brings Pediatric COVID-19 Vaccine Trials to Columbus Families

Enrollment begins for Pfizer-BioNtech clinical trial to evaluate its BNT162b2 COVID-19 vaccine in children aged 6 months to 11 years and Novavax clinical trial to assess NVX-CoV2373 for the prevention of COVID-19 in 12-17-year-old adolescents.

Read the full article here

Aventiv Research Enters Strategic Alliance With hyperCORE International, Advances Clinical Research Capabilities

Columbus-based clinical research company collaborates with super network to advance the efficiency of its clinical trials and expand expertise across vaccine, internal medicine, dermatology, and many additional therapeutic areas.

Read the full article here

Otterbein Instructor Newcomb Makes Vaccine Possible for Her Students — and Everyone Else

Senior Lecturer Suzanne Newcomb stepped away from her piano last summer to roll up her sleeve and participate in a Pfizer vaccine study.

Read the full article here

Local Volunteers and Researchers Participate in COVID-19 Vaccine Trials

Meet three Central Ohioans who participated in the Pfizer COVID-19 vaccine study at Aventiv Research.

Read the full article here

Pfizer, BioNTech to accelerate offer of Covid vaccine to placebo volunteers

The decision represents the conclusion of a complex and public kabuki dance between the companies and regulators.

Read the full article here

Columbus youngsters sought for COVID-19 vaccine trial

Aventiv Research is enrolling healthy volunteers ages 12-15 in the Columbus area for the trial.

Read the full article here

Columbus research facility looking into COVID-19 treatment

Major news in the effort to treat patients with COVID-19. A Columbus based medical research company is spearheading a potential medication.

Read the full article here

Could Columbus help find COVID cure? – 614NOW

Aventiv Research is conducting a new COVID-19 clinical trial in Columbus, Ohio, and unlike some of the vaccine trials that have recently been announced, this test requires volunteers who have already tested positive for the virus.

Read the full article here

Aventiv Research Begins Recruiting Adults Who Recently Tested Positive for COVID-19 for Clinical Trial

BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful laboratory studies.

Read the full article here

Local man one of hundreds volunteering for COVID-19 vaccine study

The race to find a vaccine that will help prevent COVID-19 is reaching the final stages of research in the United States, and a local man is among those volunteering to be injected with the investigative drug at Aventiv Research.

Read the full article here

Vaccinate me: North Canton man volunteers for COVID-19 study

Pfizer vaccine candidate being tested at Aventiv Research in Columbus.

Read the full article here

Aventiv Research Announces Participation and Local Enrollment for Late Stage Global Study of mRNA Vaccine Candidate Against COVID-19

Dr. Samir Arora, President & Medical Director will lead the Aventiv Research study program.

Read the full article here

Leading Clinical Research Center, Aventiv Research, Appoints New Chief Financial Officer

Seasoned Financial Executive Jeff Bruner Joins Aventiv Research.

Read the full article here

Aventiv Research Hires Robert Wessel to Lead Phase 1 Clinical Pharmacology Unit in Columbus

20-year business development veteran will drive Aventiv's continued growth in the early pharmaceutical sciences market.

Read the full article here

Aventiv Research Expands its Footprint in Columbus with Acquisition of Comprehensive Women's Care Research Associates

Aventiv Research Women's Health will offer clinical studies designed to bring medical advancements and opportunities to women in Central Ohio in key therapeutic areas.

Read the full article here